iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

INTRODUCTION: The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemoeller, Elisabeth, Souhami, Elisabeth, Wu, Yujun, Jensen, Klaus H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801222/
https://www.ncbi.nlm.nih.gov/pubmed/29143919
http://dx.doi.org/10.1007/s13300-017-0336-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801222/
https://www.ncbi.nlm.nih.gov/pubmed/29143919
http://dx.doi.org/10.1007/s13300-017-0336-6

Ejemplares similares